Open-Label Extension Study of JM-010 in Parkinson's Disease Patients With Dyskinesia
Latest Information Update: 22 Oct 2024
At a glance
- Drugs Buspirone/Zolmitriptan (Primary)
- Indications Dyskinesias; Parkinson's disease
- Focus Adverse reactions
- Sponsors Contera Pharma
Most Recent Events
- 14 Oct 2024 Status changed from recruiting to discontinued.
- 01 Oct 2023 This study has been completed in France, as per European Clinical Trials Database record
- 29 Aug 2022 New trial record